| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Nitric oxide |
Is a |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Formoterol fumarate |
Is a |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Ipratropium (substance) |
Is a |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Sympathomimetic agent (substance) |
Is a |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Respiratory smooth muscle relaxant |
Is a |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine and sodium benzoate injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Poisoning caused by bronchodilator drug |
Causative agent (attribute) |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Accidental poisoning caused by bronchodilator drug |
Causative agent (attribute) |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Intentional poisoning caused by bronchodilator drug |
Causative agent (attribute) |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Poisoning caused by bronchodilator drug of undetermined intent |
Causative agent (attribute) |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Bronchodilator preparations adverse reaction |
Causative agent (attribute) |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Bronchodilator preparations allergy |
Causative agent (attribute) |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Bronchodilator preparations overdose |
Causative agent (attribute) |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Accidental bronchodilator preparations overdose |
Causative agent (attribute) |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Intentional bronchodilator preparations overdose (disorder) |
Causative agent (attribute) |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Bronchodilator preparations overdose of undetermined intent |
Causative agent (attribute) |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
1 |
| Anticholinergic bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Xanthine bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Compound bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing xanthine (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Medicinal product acting as bronchodilator (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine 5mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine citrate 20mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine citrate 20mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 356.4 milligram and caffeine 30 milligram and dihydrocodeine tartrate 16 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine + ergotamine tartrate 100mg/2mg suppository (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing formoterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin + caffeine + orphenadrine citrate tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Caffeine-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Oxitropium (substance) |
Is a |
True |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing leukotriene receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing fluticasone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50micrograms/blister disks+disk inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 100micrograms/blister disks+disk inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 250micrograms/blister disks+disk inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50micrograms/blister disks refill |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 100micrograms/blister disks refill |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 250micrograms/blister disks refill |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 25micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 125micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 250micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 500micrograms/blister disks+disk inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 500micrograms/blister disks refill |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 100micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 250micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 500micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 0.5mg/2mL nebulization unit |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 2mg/2mL nebulization unit |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 250micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate topical preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50micrograms aqueous nasal spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 400micrograms single-use nasal drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 500 microgram/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate 50 microgram/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Respiratory fluticasone |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone-containing product in nasal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing fluticasone in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Respiratory smooth muscle relaxant |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate [respiratory use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone [nose] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Fluticasone propionate[skin] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Dyphylline 125mg/mL injection solution 2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Dyphylline 160mg/15ml elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guaifenesin 1.2 gram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 50mg/1mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 400mg/10 mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 800 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 100mg/5mL oral liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guaifenesin 300 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Dyphylline 100mg/15mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Diprophylline 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Diprophylline 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guaifenesin 50 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
| Guaifenesin 1 g oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bronchodilator (substance) |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]